RCT | Patient preference and treatment satisfaction with a port delivery system for Ranibizumab vs. intravitreal injections in patients with neovascular age-related macular degeneration.

Patient Preference and Treatment Satisfaction With a Port Delivery System for Ranibizumab vs Intravitreal Injections in Patients With Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial – JAMA Ophthalmology

Commentary: Port Delivery System Preferred Over Intravitreal Injection for Patients with nAMD – HCPLive

Commentary on Twitter

In the phase 3 Archway trial, mean overall treatment satisfaction scores were high in port delivery system & intravitreal injection arms; pts with neovascular AMD preferred treatment via the PDS with ranibizumab vs previous intravitreal injections https://t.co/NYf0aKpKaD

— JAMAOphthalmology (@JAMAOphth) August 25, 2022